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Abstract
Antibiotic resistance is a major public health threat, further complicated by unexplained treatment 
failures caused by bacteria that appear antibiotic susceptible. We describe an Enterobacter cloacae 
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isolate harbouring a minor subpopulation that is highly resistant to the last-line antibiotic colistin. 
This subpopulation was distinct from persisters, became predominant in colistin, returned to 
baseline after colistin removal and was dependent on the histidine kinase PhoQ. During murine 
infection, but in the absence of colistin, innate immune defences led to an increased frequency of 
the resistant subpopulation, leading to inefficacy of subsequent colistin therapy. An isolate with a 
lower-frequency colistin-resistant subpopulation similarly caused treatment failure but was 
misclassified as susceptible by current diagnostics once cultured outside the host. These data 
demonstrate the ability of low-frequency bacterial subpopulations to contribute to clinically 
relevant antibiotic resistance, elucidating an enigmatic cause of antibiotic treatment failure and 
highlighting the critical need for more sensitive diagnostics.
Antibiotic resistance threatens the delivery of safe and effective healthcare1 and is projected 
to lead to 10 million annual deaths worldwide by 20502. Failure of antibiotic treatment 
results in increased length of patient stay, healthcare costs and mortality2. Multi-drug 
resistant Enterobacter spp. have increasingly emerged as a cause of hospital-acquired 
infections3–5, with the drug colistin being relied on as a last line of treatment6,7. However, 
colistin-resistant strains have emerged, further limiting treatment options8. Further 
complicating the treatment of some bacterial infections is the failure of antibiotic therapy in 
strains that are classified as susceptible; these infections may be non-responsive to treatment 
in ~10% of cases9. Although relatively little is known about the causes of treatment failures, 
we show here that they can be mediated by antibiotic-resistant subpopulations in 
Enterobacter cloacae. Furthermore, such antibiotic-resistant subpopulations can be 
undetectable by current diagnostic tests.
Results
Phenotypically resistant subpopulation
A strain of E. cloacae was isolated from a renal transplant recipient10 and was observed to 
harbour a distinct subpopulation with resistance to colistin, visualized as numerous colonies 
within the zone of inhibition on testing by colistin Etest (we refer to the strain as ‘R/S’, to 
indicate the presence of both resistant and susceptible subpopulations) (Fig. 1a). This was 
not observed with either colistin-susceptible or -resistant (Supplementary Fig. 1) clinical 
strains. A population analysis profile (PAP) of R/S, in which a strain is assayed for survival 
on agar plates with increasing amounts of antibiotics, revealed a major proportion of the 
bacteria (>90%) susceptible to 1 μg ml−1 colistin and a highly resistant subpopulation able to 
withstand at least 500 μg ml−1 colistin (Fig. 1b). This was in contrast to the susceptible 
strain, which was uniformly killed by 1 μg ml−1 colistin, and the resistant strain, which was 
uniformly killed by 200 μg ml−1 colistin. The proportion of the R/S colistin-resistant 
subpopulation was increased to upwards of 80% on exposure to colistin (Fig. 1c). Further 
analysis revealed that this increase was due to an initial selection against the colistin-
susceptible population over the first 2 h of antibiotic exposure, followed by robust 
replication and expansion of the resistant population in the presence of the drug (Fig. 1d). 
Importantly, this suggests that the resistant cells are not persisters, which do not significantly 
expand in number during antibiotic treatment11–13. The increase in the resistant 
subpopulation was reversible, as subsequent growth after subculture in antibiotic-free media 
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led to a return of these cells to pre-treatment levels (Fig. 1c). This suggests that the resistant 
subpopulation is not the result of a stable mutation. Furthermore, bacteria from within the 
zone of inhibition (where antibiotic levels are high) and outside this region (where antibiotic 
is low or not present) on a colistin Etest plate exhibited identical levels of susceptible and 
resistant populations after serial culturing in the absence or presence of colistin 
(Supplementary Fig. 2), suggesting that the bacteria from these two growth conditions are 
identical. Indeed, deep sequencing of R/S grown with and without colistin (conditions in 
which the resistant population accounted for the vast majority or minority of the total 
population, respectively, as summarized in Supplementary Fig. 3) revealed identical 
genomes. Taken together, these data show that a minor antibiotic-resistant subpopulation is 
capable of replicating in the presence of antibiotic, becoming predominant and mediating 
resistance to high levels of drug.
To determine whether the increase in the proportion of the resistant subpopulation occurs 
during antibiotic treatment in vivo, we infected mice with R/S and treated them with colistin 
or PBS. In colistin-treated mice, we observed a significant increase in the frequency of the 
resistant subpopulation of bacteria isolated from the peritoneum (Fig. 1e) and liver 
(Supplementary Fig. 4). Surprisingly, there was also a robust increase in the resistant 
subpopulation during in vivo infection in the absence of colistin treatment (Fig. 1e and 
Supplementary Fig. 4). By 48 h, the percentage of the resistant subpopulation increased 
from <10% to >80% (Supplementary Fig. 5). These results highlight the process of infection 
as leading to a significant increase in the frequency of an antibiotic-resistant subpopulation 
of bacteria.
Resistance to innate immune defences
Various host pressures could be responsible for the increase in the colistin-resistant 
subpopulation during infection. As macrophages are a major component of the early 
immune response14, we tested their role by depleting these cells with clodronate liposomes15 
(Supplementary Fig. 6) and subsequently infecting mice with R/S. In contrast to bacteria 
recovered from mice treated with control liposomes, which demonstrate a robust increase in 
the frequency of the resistant subpopulation, those recovered from macrophage-depleted 
mice showed no such increase (Fig. 2a). Based on these results, we next determined whether 
macrophages were sufficient to cause the increase in the resistant subpopulation, by 
infecting them in vitro. During macrophage infection, the colistin-resistant subpopulation 
increased to 40% within only 2 h (Fig. 2b). This rise was dependent on internalization of the 
bacteria, because preventing phagocytosis with cytochalasin D abrogated this phenomenon 
(Fig. 2b). Therefore, macrophages are both required and sufficient for the increased 
frequency of the resistant subpopulation during infection, underlining a role for a specific 
innate immune cell type in this process.
Macrophages possess many antimicrobials16, and we hypothesized that specific components 
would be required for the increase in the frequency of the resistant subpopulation, testing 
reactive oxygen species (formed after treatment with hydrogen peroxide), lysozyme and the 
murine cationic antimicrobial peptide CRAMP. All of these antimicrobials resulted in a 
dose-dependent increase in the frequency of the colistin-resistant subpopulation in vitro 
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(Fig. 2c–e), as did LL-37, the human orthologue of CRAMP (Supplementary Fig. 7). These 
results led us to test whether the antimicrobials were responsible for the increase in the 
resistant subpopulation during in vivo infection. We infected wild-type (WT) and triple 
knockout (TKO) mice lacking a functional NADPH oxidase (which leads to the production 
of reactive oxygen species17), lysozyme and CRAMP. TKO mice were more susceptible to 
infection by R/S as they harboured over ten times more bacteria than WT mice 
(Supplementary Fig. 8), demonstrating the importance of these antimicrobials in host 
defence. Although a robust increase in the frequency of the resistant subpopulation was 
observed in wild-type mice, this was abrogated in TKO mice (Fig. 2f). The frequency of the 
resistant subpopulation in mice lacking one of these three antimicrobials was not 
significantly different from that in WT mice, but it was decreased in double KO mice 
lacking the NADPH oxidase and CRAMP or lysozyme (Supplementary Fig. 9). These data 
identify a role for specific host innate immune antimicrobials in the increase of an antibiotic-
resistant subpopulation during in vivo infection.
Subpopulation-mediated antibiotic failure
To determine the relevance of the increase in frequency of the resistant subpopulation during 
in vivo infection, we tested whether the R/S strain was able to resist colistin treatment. We 
infected mice with either R/S or a colistin-susceptible strain, and treated the mice with PBS 
(as a control) or high doses of colistin after establishment of infection to simulate the 
progression of infection and treatment in the clinic. The levels of the susceptible strain in the 
peritoneum (Fig. 3a) and liver (Fig. 3b) were significantly reduced by colistin treatment. In 
contrast, the R/S strain was refractory to treatment with colistin as its levels were unchanged 
between the treated and untreated groups (Fig. 3a,b). In a timecourse experiment, the level 
of the susceptible strain was reduced by 3 logs at 42 h, whereas the level of the R/S strain 
was not diminished by colistin treatment, but instead increased by roughly tenfold 
(Supplementary Fig. 10). These data suggest that the presence of the resistant subpopulation 
results in inefficacy of colistin to reduce bacterial levels in vivo. Furthermore, these results 
provide in vivo evidence that the resistant subpopulation does not behave like persisters, 
which do not significantly expand in number during antibiotic treatment.
We next tested whether the role of the host immune system in the increase of the resistant 
subpopulation was directly responsible for the inefficacy of antibiotic therapy. We first found 
that colistin treatment of R/S-infected mice could cause a significant reduction in bacterial 
levels if initiated at the time of infection (before the increase in the frequency of the resistant 
subpopulation), but not if it was delayed until only 4 h after infection (Fig. 3c). However, in 
macrophage-depleted mice, treatment with colistin at 4 h became effective, leading to a 
reduction in bacterial levels (Fig. 3c) and indicating that the host-driven increase in the 
frequency of the resistant subpopulation is responsible for the inefficacy of antibiotic 
treatment.
To further test the relevance of this phenomenon in vivo, we infected mice with a lethal dose 
of bacteria and treated with either PBS or colistin after 12 h. Both the susceptible and R/S 
strains led to lethal infections in the absence of colistin (Fig. 3d,e). In the presence of 
colistin, only mice infected with the susceptible strain were rescued (Fig. 3d), whereas those 
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infected with R/S still succumbed to infection within 100 h (Fig. 3e). These data 
demonstrate the impact of an antibiotic-resistant subpopulation in mediating a lethal 
infection during high-dose antibiotic treatment.
PhoQ-dependent resistant subpopulation
We next set out to determine the molecular mechanism underlying the phenotype of the 
resistant subpopulation. RNAseq analysis was conducted (Supplementary Fig. 3 and 
Supplementary Table 1) to determine whether there were transcriptional differences between 
the susceptible and resistant subpopulations of R/S. In total, this analysis revealed 325 genes 
upregulated and 360 genes downregulated in the resistant subpopulation as compared to the 
susceptible subpopulation (Supplementary Table 2). This approach should detect differences 
between the two subpopulations, but it may also identify expression differences due to 
colistin treatment. Among the upregulated genes, we noticed a signature (Supplementary 
Table 3) associated with the two-component histidine kinase PhoQ (refs 18–25), which has 
previously been implicated in polymyxin resistance, in part through its role in modification 
of the lipid A portion of lipopolysaccharide26. To validate the RNAseq data, we confirmed 
that the resistant subpopulation expressed higher levels of the predicted lipid A modification 
genes arnB and eptA (ref. 27) (Supplementary Fig. 11). These data suggested that R/S 
displayed a modified lipid A profile, which we confirmed by thin-layer chromatography 
(Supplementary Fig. 12). Furthermore, modified lipid A species increased in abundance 
during growth of R/S in the presence of colistin, consistent with their expression by the 
resistant subpopulation (Supplementary Fig. 12). To test whether the lipid A modifications 
were dependent on PhoQ, we constructed an R/S deletion mutant lacking phoQ (ΔphoQ). 
Indeed, lipid A from the ΔphoQ strain lacked the specific lipid A modifications observed in 
WT R/S that were enhanced in the presence of colistin, which were restored in a phoQ 
complemented strain (Supplementary Fig. 12). Thus, the R/S resistant subpopulation 
exhibits PhoQ-dependent lipid A modifications and is transcriptionally distinct from the 
susceptible subpopulation.
To interrogate the potential contribution of PhoQ to the R/S resistance phenotype, we 
examined the colistin resistance profile of ΔphoQ. Strikingly, the ΔphoQ strain exhibited a 
complete absence of the resistant subpopulation by Etest, while the susceptible 
subpopulation remained unaffected, as the border of the zone of clearing was unaltered from 
that of WT R/S (Fig. 4a). Complementation with phoQ restored the presence of the resistant 
subpopulation (Fig. 4a). This was also confirmed by PAP, where ΔphoQ lacked the resistant 
subpopulation present in R/S and behaved in a similar manner to the susceptible strain (Fig. 
4b). Importantly, R/S and ΔphoQ harboured equivalent levels of persisters, clearly indicating 
that the colistin-resistant subpopulation (which depends on PhoQ) is not made up of 
persister cells (Supplementary Fig. 13). The phoQ mutant also exhibited no colistin-resistant 
subpopulation after exposure to host antimicrobials (Supplementary Fig. 14a), during 
macrophage infection (Supplementary Fig. 14b) or during in vivo infection (Supplementary 
Fig. 14c). Without the presence of the resistant subpopulation, ΔphoQ was susceptible to 
colistin treatment in vivo, exhibiting a significantly decreased bacterial load (Fig. 4c). 
Furthermore, the ability of colistin to rescue mice from an otherwise lethal inoculum was 
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restored during infection with ΔphoQ (Fig. 4d). Thus, the presence of the colistin-resistant 
subpopulation is dependent on PhoQ, which is required for a lethal drug-resistant infection.
Undetected resistant subpopulation
The size of the resistant subpopulation can vary greatly between strains, as exemplified by a 
distinct E. cloacae clinical isolate (termed R/S-lo) that harbours a colistin-resistant 
subpopulation comprising between 0.01 and 0.001% of the total population (Fig. 5a), over 
1,000-fold less prevalent than that of R/S when grown in media without antibiotic. Similar to 
R/S, the increase of the R/S-lo resistant subpopulation in the presence of colistin 
(Supplementary Fig. 15) was due to initial selection against the susceptible subpopulation 
followed by expansion of the resistant subpopulation (Supplementary Fig. 16). The 
frequency of the resistant subpopulation was similarly increased by treatment with H2O2, 
lysozyme, CRAMP and LL-37 (Supplementary Fig. 17), during macrophage infection 
(Supplementary Fig. 18) and during in vivo infection of mice (Supplementary Fig. 19), and 
was greatly diminished in macrophage-depleted (Supplementary Fig. 20) and TKO mice 
(Supplementary Fig. 21). These data revealed that, similar to R/S, the frequency of the 
resistant subpopulation of R/S-lo is increased by colistin as well as the activity of specific 
host innate immune components. During in vivo infection, although the levels of a 
susceptible strain were significantly reduced by colistin treatment, the levels of R/S-lo were 
unaffected (Supplementary Fig. 22). These data directly correlated with a failure of colistin 
therapy to rescue R/S-lo infected mice from a lethal infection (Fig. 5c), whereas mice 
infected with a susceptible strain were completely rescued (Fig. 5b). Importantly, unlike R/S, 
R/S-lo was clinically classified as being susceptible to colistin, as the resistant subpopulation 
(present at a frequency of only 1 in 10,000 c.f.u.) was not detected by Etest (Fig. 5d). 
Therefore, this seemingly colistin-susceptible strain, harbouring an undetected resistant 
subpopulation, is capable of causing an antibiotic-resistant and lethal infection in vivo.
It is worrisome that R/S-lo was not identified as colistin-resistant, and we wondered whether 
the resistant population could be detected by diagnostic testing when it is more frequent 
during host infection. We directly plated peritoneal lavage samples from infected mice in the 
absence of subculture and were able to detect the R/S-lo resistant subpopulation by Etest, as 
indicated by colonies within the zone of inhibition (Fig. 5e,g). In contrast, when these 
samples were processed by the clinical microbiology laboratory (as would occur with a 
sample from a human patient and including a critical subculture step), Etest could no longer 
detect the diminished resistant subpopulation (Fig. 5f,g). Strikingly, these data reveal how 
and when detection of the resistant subpopulation can be missed during routine diagnostic 
testing and how this can translate into an unexplained failure of antibiotic therapy.
Discussion
The findings presented here highlight the role of a minor colistin-resistant bacterial 
subpopulation in mediating antibiotic treatment failure in vivo. This resistant subpopulation 
is genetically identical to the susceptible subpopulation, but exhibits differences in gene 
expression and lipid A modification. Furthermore, the presence of this resistant 
subpopulation is dependent on the histidine kinase PhoQ. The data also highlight an 
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unexpected role for specific host innate immune components (lysozyme, CRAMP and 
H2O2) in the increase of the antibiotic-resistant subpopulation during infection. The increase 
in the frequency of the resistant subpopulation induced by host immune pressure in vivo was 
shown to be critical for eventual failure of colistin therapy.
Like bacterial persistence, the phenotypic resistance phenomenon we describe involves a 
resistant subpopulation, but there are important differences. Persistence involves a small 
subpopulation of bacteria that are tolerant to a drug due to a state of low metabolic activity, 
with no or limited replication28. Wakamoto et al. showed that, in some cases, persisters can 
replicate, although it is at a very low rate and is insufficient to cause an overall increase in 
the numbers of the population11. In contrast, we describe a resistant subpopulation that 
rapidly replicates both in vitro and in vivo in the presence of antibiotic and leads to a very 
significant overall increase in bacterial population level (Fig. 1d and Supplementary Fig. 
10). Furthermore, we directly show that the PhoQ-dependent colistin-resistant subpopulation 
is distinct from persisters, which are also present but independent of PhoQ (Supplementary 
Fig. 13). Several papers have recently demonstrated the importance of persisters as a 
reservoir of infection during antibiotic treatment in vivo12, which can continue to replicate 
after treatment has been stopped, leading to relapse13. In contrast, we demonstrate that the 
colistin-resistant subpopulation described here facilitates bacterial growth and subsequent 
host lethality, even in the presence of antibiotic. Persistence has also been linked to immune 
pressure, as bacterial populations within macrophages can have increased numbers of 
persisters29. We observe a similar link; both in vitro and in vivo, specific host antimicrobials 
lead to an increased frequency of the resistant subpopulation. Taken together, both persisters 
and the resistant subpopulation described here highlight the ability of a minority of a 
bacterial population to exert a striking effect on the outcome of infection and antibiotic 
treatment. Persisters are kept at bay by antibiotic treatment and form a reservoir that can 
cause relapse, but the colistin-resistant subpopulation described here has the ability to cause 
acute infection and lethality during the course of antibiotic treatment.
We propose to refer to the resistance phenomenon described here as ‘clonal 
heteroresistance’. The phenomenon of heteroresistance, in which a resistant subpopulation 
exhibits an increased level of antibiotic resistance relative to the larger susceptible 
subpopulation, was described as far back as 1947 (ref. 30). However, its relevance to 
infection and resistance has remained unclear, and even its definition has been debated. We 
use the term clonal heteroresistance to distinguish the phenomenon we describe from the 
blanket term heteroresistance, which is often used to refer to mixed populations of 
genetically distinct bacteria31–34. We show that clonal heteroresistance, in addition to 
mediating lethal infection in the presence of antibiotic, can also go undetected and cause 
unexplained treatment failure during in vivo infection (Supplementary Fig. 23). Current 
widely used methods of antibiotic susceptibility testing rely on in vitro culture and analysis. 
Our data show that these methods can greatly alter results and present an inaccurate picture 
of the level of in vivo resistance. Our findings highlight both a need and opportunity for 
improved diagnostics to detect antibiotic-resistant subpopulations and ultimately prevent 
such treatment failures.
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E. cloacae strain R/S was isolated from a blood sample from a renal transplant recipient at 
Emory University Hospital, Atlanta, GA. E. cloacae R/S-lo, the colistin-susceptible strain 
Mu819 and the colistin-resistant strain Mu117 were isolated from urine samples from 
patients at other Atlanta hospitals.
Bacterial culture
All bacterial strains were streaked on Mueller–Hinton (MH) agar plates and grown in MH 
medium at 37 °C in a shaking incubator from a single colony before each experiment. 
Numbers of c.f.u. were determined by plating dilutions on MH agar plates incubated at 
37 °C and then counting bacterial colonies at the lowest distinguishable dilution.
Bacterial genetics
To generate strain ΔphoQ, 600–700 bp upstream and downstream fragments of the genomic 
region surrounding phoQ were PCR-amplified with primers 81 and 118, and 82 and 119, 
respectively (Supplementary Table 4), and fused with the hygromycin resistance cassette 
HmR amplified from vector pMQ310 with primers 79 and 80 (ref. 35) using splicing by 
overlap extension (SOE) PCR (ref. 36). The suicide vector pEXR6K was generated by 
replacing the pMB1 ori from PCR linearized plasmid pEX100T (ref. 37) using primers 110 
and 111 with the R6K ori amplified from plasmid pMQ310 with primers 108 and 109 using 
the Gibson Assembly Cloning Kit (Invitrogen). The HmR construct was inserted into SmaI 
(New England Biolabs) digested pEXR6K by Gibson assembly and the resulting plasmid 
was transformed to strain R/S by electroporation.
Transformants were selected on MH agar containing 150 μg ml−1 hygromycin (Sigma) then 
passaged to Luria-Bertani (LB) agar containing 20% sucrose and no NaCl to counterselect 
for vector loss. Chromosomal replacement of phoQ with the hygromycin marker was 
confirmed by Sanger sequencing. To generate strain phoQ-comp, the promoter region of the 
phoPQ operon was amplified with primers 142 and 143 and fused by SOE PCR to gene 
phoQ amplified with primers 144 and 145. The resulting construct was inserted to plasmid 
pBAV-1K-T5-GFP (ref. 38) PCR linearized with primers 146 and 147 to create the 
complementation vector. The vector was transformed to strain ΔphoQ by electroporation and 
selected on MH agar containing 90 μg ml−1 kanamycin (Sigma).
Antibiotic susceptibility testing
The colistin susceptibility of all strains was determined using the Etest method. Briefly, the 
inoculum was prepared from colonies grown on a 5% sheep blood agar plate (Remel, 
Lenexa, KS) for 18 h. Several colonies were suspended in 0.9% sterile saline (Remel) and 
adjusted to a concentration equivalent to a 0.5 McFarland turbidity standard. The suspension 
was used to streak a 100-mm-diameter MH agar plate and the Etest strip (bioMérieux) was 
placed on it. The plate was incubated at 35 °C for 20 h and the minimum inhibitory 
concentration (MIC) was read where inhibition of growth intersected the Etest strip. Small 
colonies that grew within the zone of inhibition were included in the MIC determination. 
Band et al. Page 8
















Etest analyses of samples from mouse infections were plated directly from peritoneal lavage 
samples without subculturing. PAPs were performed by growing bacteria to mid-log phase 
and then plating on MH agar containing various concentrations of colistin. Percentage 
colistin resistance was calculated as the number of bacteria that grew on 100 μg ml−1 colistin 
divided by the number of bacteria that grew on MH alone.
Mice
WT C57BL/6J mice were purchased from Jackson Laboratories and used at age 8–10 weeks; 
all experiments used age- and sex-matched mice. TKO mice deficient in the gp91 
component of the NADPH oxidase, lysozyme and CRAMP, as well as double knockout mice 
lacking two of the indicated antimicrobials, were derived by crossing cybb−/− (gp91, Jackson 
Laboratories), lysM−/− (lysozyme; generously provided by D. Portnoy, UC Berkeley) and 
cnlp−/− (CRAMP; Jackson Laboratories) mice. TKO mice were investigated for health 
defects by histology and bacterial culture of various organs, with no overt health differences 
observed in uninfected TKO mice when compared to WT. Mice were housed under specific-
pathogen-free conditions in filter-top cages at Yerkes National Primate Center, Emory 
University, and provided food and water ad libitum. All experimental procedures were 
approved by the Emory University Institutional Animal Care and Use Committee (IACUC). 
Sample size, as reported in the figure legends, was determined by allowing for significance 
by the Mann–Whitney test (n ≥ 4) while minimizing the number of animals used, and five 
mice were thus used per group for the majority of experiments. No randomization or 
blinding was done in the animal studies.
Mouse infections
Approximately 5 × 107 c.f.u. were administered per mouse for infections to quantify the 
bacterial load, and approximately 2 × 108 c.f.u. were administered for survival experiments. 
Bacterial inocula were suspended in PBS and 100 μl was inoculated intraperitoneally (i.p.) 
to each mouse. Colistin methanesulfonate was injected i.p. in 100 μl PBS at a dosage of 10 
mg per kg per dose. Mice were monitored by weight and were euthanized if found to be 
below 80% starting weight, as mandated by the IACUC protocol. Mice were euthanized, and 
the liver, spleen and peritoneal lavage samples were collected into sterile PBS. Solid organ 
samples were homogenized using a tissue-tearor (BioSpec), and all samples were plated for 
c.f.u. and per cent colistin resistance.
Macrophage depletion
Macrophages were depleted from mice using clodronate liposomes 
(clodronateliposomes.com). Mice were injected with 200 μl liposomes i.p. 3 days before 
infection and then injected again with 100 μl liposomes i.v. 1 day before infection. Mice 
were infected i.p. for 8 h before peritoneal lavage fluid was collected and plated for c.f.u. 
Part of this sample was also used for flow cytometry to confirm macrophage depletion.
Macrophage infection
Macrophages were derived from the bone marrow of mice. Briefly, femurs from mice were 
removed and whole bone marrow was flushed out. The bone marrow cells were grown in 
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media containing DMEM, 10% fetal bovine serum (FBS) and macrophage colony-
stimulating factor (M-CSF), which induces the differentiation and growth of macrophages. 
After confluent layers of macrophages were derived, cells were plated into 24-well plates at 
3 × 105 cells per well. Bacteria were added to the wells at 3 × 106 c.f.u. per well for a 
multiplicity of infection (MOI) of 10:1. Plates were centrifuged to synchronize the infection. 
After 30 min, the macrophages were washed and 100 μg ml−1 of gentamicin was added to 
the media to remove and prevent the growth of extracellular bacteria. At 1, 2 and 4 h post-
infection, macrophages were incubated with 1% saponin in PBS for 2 min to lyse open cells 
and remove bacteria. Samples were then plated for c.f.u., and per cent colistin resistance 
calculated. To prevent internalization of bacteria, some wells were pretreated with 1 μg ml−1 
cytochalasin D for 30 min before the addition of bacteria.
Flow cytometry
Peritoneal lavage fluid was stained with F4/80-PE/Cy7 (BM8) (Biolegend) and CD11b-
APC/A700 (M1I70) (eBioscience) antibodies for 35 min. Red blood cells (RBCs) were 
lysed with RBC lysis buffer (Becton Dickinson) for 5 min. Cells were fixed with 1% 
paraformaldehyde and analysed on an LSRII flow cytometer (BD). Macrophages were 
defined as F4/80+CD11b+ cells.
DNA and RNA isolation
An overnight liquid culture of R/S grown at 37 °C in MH broth was back-diluted in triplicate 
to either fresh MH broth or MH broth containing 100 μg ml−1 colistin to enrich for 
susceptible or colistin-resistant bacteria, respectively. Cultures were grown to exponential 
phase at 37 °C and collected for DNA and RNA isolation. Numbers of c.f.u. were calculated 
as above. DNA was isolated using the DNEasy Blood and Tissue Kit (Qiagen) following the 
Gram negative bacteria protocol with RNase treatment. RNA was isolated using a modified 
phase extraction method39 with initial incubation in TriReagent (Zymo) followed by phase 
separation with chloroform. RNA was precipitated from the aqueous phase with isopropanol 
and 1.2 M NaCl at 4 °C, and further purified with the Directzol RNA Kit (Zymo) following 
the recommended DNase treatment step.
DNA and RNA sequencing
Sample integrities were verified with the Agilent 2100 Bioanalyzer. DNA libraries were 
prepared using the NexteraXT DNA kit (Illumina). For RNA libraries, samples were first 
depleted of ribosomal RNAs using the Ribo-Zero rRNA Removal Kit (Illumina) and 
libraries prepared using the EpiCentre ScriptSeq Complete (Bacteria) Low Input kit 
(Illumina). Next-generation short sequence reads were generated with the Illumina HiSeq 
1000 platform at the Yerkes National Primate Research Center Nonhuman Primate 
Genomics Core (http://www.yerkes.emory.edu/nhp_genomics_core/). Long sequence reads 
were generated with the PacBio II platform using P5-C3 chemistry at the Duke University 
Sequencing and Genomic Technologies Shared Resource.
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De novo genome assembly and sequence analysis
A hybrid de novo assembly was performed using both Illumina and PacBio data using 
Celera Assembler version 8.2 (ref. 40). The sequence data resolved into two contigs, one 
representing the chromosome and the other representing the plasmid. The quality of the 
assembly was confirmed by analysis using the ALE tool41. The assembly was automatically 
annotated using the NCBI prokaryotic annotation pipeline. Illumina whole shotgun 
sequences of the samples enriched for colistin resistance (COL) and colistin susceptibility 
(MH) were aligned against the assembled genome using bwa-0.7.12 (ref. 42) and visualized 
with the samtools-1.2 mpileup function43. Single nucleotide polymorphisms between the 
assembled genome and short sequence reads were manually analysed to determine sequence 
conservation between COL and MH samples.
RNAseq analysis
Single-end Illumina libraries from reverse-transcribed RNA were mapped against the 
Enterobacter de novo assembled reference using Bowtie2 (ref. 44). Differential gene 
expression between the three colistin-treated strains and controls was quantified by the 
cufflinks/cuffdiff tools in CufflinksVersion 2.2.1 (refs 45,46). Sequences of differentially 
expressed genes with significant q-values were analysed with Blast2Go software version 
3.1.3 to identify the Escherichia coli gene orthologue and putative function47.
Quantitative reverse transcriptase PCR (qRT-PCR)
RNA was collected as described above. One-step qRT-PCR was performed using the Power 
SYBR Green RNA-to-Ct kit (Applied Biosystems) with primers (Supplementary Table 4) on 
a StepOnePlus Real-time PCR System (Applied Biosystems) according to the 
manufacturer’s instructions. rpoD was used as the internal control gene48. Relative 
expression was calculated as 2−(ΔCt) (ref. 49).
Isolation and analysis of 32P lipid A species
E. cloacae strains were grown overnight in MH broth, diluted 1:400 in fresh MH broth 
containing appropriate selective antibiotics. For induction of the resistant phenotype, 100 μg 
ml−1 colistin (Sigma) was used. E. coli W3110 and WD101 strains were grown in LB broth 
overnight followed by a 1:100 dilution in fresh LB medium. After dilutions, cells were 
immediately labelled with 2.5 μCi ml−1 of inorganic 32P-phosphate (Perkin Elmer) and 
collected at absorbance at 600 nm (A600) = 0.5 (E. cloacae) or A600 = 1.0 (E. coli). Lipid A 
extraction, separation and visualization was performed as described previously50. Briefly, 
lipid A extraction was carried out by mild acidic hydrolysis and spotted onto a silica thin-
layer chromatography plate (10,000 c.p.m. per lane). Labelled lipid A species were 
separated using a solvent mixture of chloroform, pyridine, 88% formic acid and water 
(50:50:16:5). The thin-layer chromatography plate was exposed to a phosphoimager screen 
and visualized by phosphoimaging analysis (Bio-Rad PMI). The analysed images were 
cropped to aid in data analysis (for the full unaltered images see Supplementary Fig. 24).
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Statistical analyses were performed using Prism 5 (Graphpad Software). The significance of 
the mouse experiments was determined with the Mann–Whitney test, as not all data were 
normally distributed, and all in vitro experiments were analysed using the two-tailed 
student’s t-test (for data with a normal distribution). All experiments were repeated at least 
two to three times (and up to ten times). All replicates shown are biological replicates.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. A colistin-resistant subpopulation increases in frequency during in vivo infection
a, Testing of E. cloacae clinical isolate R/S by colistin Etest, with drug concentration 
indicated in μg ml−1. Colonies within the zone of inhibition indicate a colistin-resistant 
subpopulation. Data are representative of more than ten Etests. b, Population analysis profile 
of R/S as well as colistin-susceptible and -resistant E. cloacae clinical isolates (n = 3). c, 
Percentage of the colistin-resistant subpopulation in R/S in antibiotic-free media, after 24 h 
treatment with 100 μg ml−1 colistin and after 8 h subculture of the colistin-treated culture in 
antibiotic-free media. ‘Colistin resistant (%)’ represents the number of c.f.u. in each culture 
that can grow on media containing 100 μg ml−1 colistin, as a percentage of the total c.f.u. in 
the culture (n = 3). d, Colistin-resistant c.f.u. and total c.f.u. of R/S during 7 h treatment with 
100 μg ml−1 colistin in liquid culture (n = 3). e, Pre-infection inoculum (black bar) was used 
to infect mice and peritoneal lavage was performed and collected 24 h later and plated to 
calculate per cent colistin-resistant c.f.u. (n = 5). Mice were treated at 8, 14 and 20 h with 
colistin (grey bar) or PBS (red bar). Error bars represent standard error of the mean (s.e.m.) 
(Mann–Whitney test, *P < 0.05, **P < 0.01).
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Figure 2. Innate immune host defences are required for the increased frequency of the colistin-
resistant subpopulation during infection
a, Mice pretreated with PBS liposomes (control, grey) or clodronate liposomes (to deplete 
macrophages, red) were infected with R/S (pre-infection, black). After 8 h, peritoneal lavage 
fluid was collected and plated to calculate per cent colistin resistance (n = 5). b, Murine 
bone-marrow-derived macrophages were untreated or pretreated with cytochalasin D, 
infected with R/S, and per cent colistin resistance was calculated at the indicated time points 
(n = 6). c–e, R/S was either untreated or treated with the indicated amounts of H2O2 (c), 
lysozyme (d) or CRAMP (e) for 5 h, and per cent colistin resistance was calculated (n = 3). 
f, Wild-type (WT, grey) or triple knockout (TKO, red) mice lacking the gp91 subunit of the 
NADPH oxidase, lysozyme and CRAMP were infected with R/S (pre-infection, black). At 8 
h post-infection, peritoneal lavage fluid was collected and plated to calculate per cent 
colistin resistance (n = 5). Data are compiled from two independent experiments. Error bars 
represent s.e.m. Mann–Whitney test (**P < 0.01) in a and f; Student’s two-tailed t-test (*P < 
0.05) in b.
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Figure 3. R/S is refractory to colistin during infection and leads to colistin treatment failure
a,b, Mice infected with R/S or the susceptible isolate were treated with colistin at 8, 14 and 
20 h. Numbers of c.f.u. were quantified at 24 h in the peritoneal lavage fluid (a) and liver (b) 
(n = 5). c, Mice pretreated with PBS (left and middle panels) or clodronate (right panel) 
liposomes were infected with R/S and treated with colistin at 0 h (left panel) or 4 h (middle 
and right panels). A second dose of colistin was administered 2 h after the first; 2 h later, 
peritoneal lavage fluid was plated to enumerate c.f.u. (n = 5). d,e, Survival of mice infected 
with R/S or the colistin-susceptible isolate. Mice were treated with colistin or PBS starting at 
12 h post-infection, with additional doses given every 6 h thereafter. Surviving mice were 
monitored until day 24 (n = 5). Error bars represent s.e.m.; centre values represent the 
median. Mann–Whitney test: *P < 0.05, **P < 0.01, NS = not significant.
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Figure 4. PhoQ is required for the presence of the colistin-resistant subpopulation
a, Colistin Etest of R/S, ΔphoQ and the complement (phoQ-comp) strains, with drug 
concentration indicated in μg ml−1. Colonies within the zone of inhibition indicate a colistin-
resistant subpopulation. Data are representative of two Etests. b, Population analysis profile 
of R/S, ΔphoQ and colistin-susceptible and -resistant E. cloacae strains (n = 3). c, Mice 
infected with R/S or ΔphoQ were treated with colistin at 8, 14 and 20 h. Values of c.f.u. were 
quantified at 24 h in the peritoneal lavage fluid (n = 5). d, Survival of mice infected with R/S 
(top) or ΔphoQ (bottom). Mice were treated with colistin or PBS starting at 12 h post-
infection, with additional doses given every 6 h thereafter (n = 5). Error bars represent 
s.e.m.; centre values represent the median. Mann–Whitney test: *P < 0.05, NS = not 
significant.
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Figure 5. Clinical isolate harbouring an undetected colistin-resistant subpopulation causes a 
lethal, antibiotic-resistant infection
a, PAP of E. cloacae clinical isolate R/S-lo compared to R/S and the colistin-susceptible and 
-resistant isolates (n = 3). b,c, Infection of mice with the colistin-susceptible isolate (b) or 
R/S-lo with or without colistin treatment (c) every 6 h and initiated 12 h post-infection (n = 
5). Surviving mice were monitored until day 24. d–f, Colistin Etest results, with drug 
concentration indicated in μg ml−1, of R/S-lo from pre-infection inoculum (d), peritoneal 
lavage sample from a mouse infected for 8 h (e) and the peritoneal lavage sample 
subcultured overnight in drug-free media (f) (n = 5). Colonies in the zone of inhibition (e, 
red arrows) indicate resistant bacteria. Images are representative of five individual samples. 
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g, Samples from d–f were plated to determine per cent colistin resistance (n = 5). Error bars 
represent s.e.m.
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